Should I buy or sell ImmunoGen stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" IMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMGN, but not buy additional shares or sell existing shares. View IMGN analyst ratings or view top-rated stocks .

What is ImmunoGen's stock price target for 2024?

12 Wall Street analysts have issued 12 month price targets for ImmunoGen's shares. Their IMGN share price targets range from $16.00 to $31.26. On average, they anticipate the company's stock price to reach $25.77 in the next year. This suggests that the stock has a possible downside of 11.8%. View analysts price targets for IMGN or view top-rated stocks among Wall Street analysts .

How have IMGN shares performed in 2023?

ImmunoGen's stock was trading at $4.96 at the beginning of 2023. Since then, IMGN shares have increased by 489.1% and is now trading at $29.22. View the best growth stocks for 2023 here .

Are investors shorting ImmunoGen?

ImmunoGen saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 32,660,000 shares, an increase of 30.5% from the October 31st total of 25,030,000 shares. Based on an average daily volume of 4,780,000 shares, the short-interest ratio is currently 6.8 days. View ImmunoGen's Short Interest .

When is ImmunoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our IMGN earnings forecast .

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) announced its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.02 by $0.08. The biotechnology company earned $113.43 million during the quarter, compared to the consensus estimate of $106.98 million. ImmunoGen had a negative trailing twelve-month return on equity of 22.11% and a negative net margin of 25.56%.

What ETFs hold ImmunoGen's stock?

ETFs with the largest weight of ImmunoGen (NASDAQ:IMGN) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , Virtus LifeSci Biotech Products ETF (BBP) , Range Cancer Therapeutics ETF (CNCR) , iShares Micro-Cap ETF (IWC) , Principal Healthcare Innovators ETF (BTEC) , Invesco Nasdaq Future Gen 200 ETF (QQQS) , Invesco DWA SmallCap Momentum ETF (DWAS) and iShares Biotechnology ETF (IBB) .

What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?

16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com . Mark J. Enyedy has an approval rating of 64% among the company's employees.

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE) , NVIDIA (NVDA) , Micron Technology (MU) , Immunomedics (IMMU) , Advanced Micro Devices (AMD) , AbbVie (ABBV) , Gilead Sciences (GILD) , OPKO Health (OPK) , AT&T (T) and Dynavax Technologies (DVAX) .

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Redmile Group LLC (6.57%), RA Capital Management L.P. (5.00%), Wellington Management Group LLP (4.98%), FMR LLC (2.17%), Morgan Stanley (1.81%) and Artisan Partners Limited Partnership (1.40%). Insiders that own company stock include David G Foster, Mark J Enyedy , Renee Lentini , Stacy Ann Coen and Theresa Wingrove . View institutional ownership trends .

How do I buy shares of ImmunoGen?

Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does ImmunoGen have any subsidiaries?

The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp.. Read More

ImmunoGen Stock Price, News & Analysis (NASDAQ:IMGN)

$29.22

-0.10 (-0.34%)

(As of 12/4/2023 ET)

Compare

Today's Range: $29.05
▼
$29.28
50-Day Range: $12.46
▼
$29.35
52-Week Range: $3.61
▼
$29.44

Volume: 13.64 million shs
Average Volume: 5.68 million shs
Market Capitalization: $7.78 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.77

ImmunoGen MarketRank™ Stock Analysis

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 11.8% Downside
$25.77 Price Target
Short Interest: Bearish
12.27% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.55
Upright™ Environmental Score
News Sentiment: -0.02
Based on 52 Articles This Week
Insider Trading: Selling Shares
$13.42 M Sold Last Quarter
Proj. Earnings Growth: 414.29%
From $0.07 to $0.36 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

572nd out of 952 stocks

Pharmaceutical Preparations Industry

269th out of 434 stocks

2.1

Analyst's Opinion

Consensus Rating
ImmunoGen has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 9 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.77, ImmunoGen has a forecasted downside of 11.8% from its current price of $29.22.
Amount of Analyst Coverage
ImmunoGen has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
12.27% of the outstanding shares of ImmunoGen have been sold short.
Short Interest Ratio / Days to Cover
ImmunoGen has a short interest ratio ("days to cover") of 6.8.
Change versus previous month
Short interest in ImmunoGen has recently increased by 30.48%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
ImmunoGen does not currently pay a dividend.
Dividend Growth
ImmunoGen does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
ImmunoGen has received a 68.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.
Environmental Sustainability
The Environmental Impact score for ImmunoGen is -0.55.

2.2

News and Social Media Coverage

News Sentiment
ImmunoGen has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 52 news articles for ImmunoGen this week, compared to 4 articles on an average week.
Search Interest
48 people have searched for IMGN on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.
MarketBeat Follows
25 people have added ImmunoGen to their MarketBeat watchlist in the last 30 days. This is an increase of 525% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ImmunoGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,422,760.00 in company stock.
Percentage Held by Insiders
Only 5.07% of the stock of ImmunoGen is held by insiders.
Percentage Held by Institutions
90.50% of the stock of ImmunoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for ImmunoGen are expected to grow by 414.29% in the coming year, from $0.07 to $0.36 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ImmunoGen is -94.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ImmunoGen is -94.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ImmunoGen has a P/B Ratio of 41.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ImmunoGen Stock (NASDAQ:IMGN)

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

IMGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMGN Stock News Headlines

December 5, 2023 | americanbankingnews.com

ImmunoGen's (IMGN) "Neutral" Rating Reaffirmed at Piper Sandler

December 4, 2023 | realmoney.thestreet.com

ImmunoGen downgraded to Neutral from Overweight at Piper Sandler

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

December 4, 2023 | businesswire.com

IMMUNOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ImmunoGen, Inc. - IMGN

December 4, 2023 | finance.yahoo.com

Are You Looking for a Top Momentum Pick? Why ImmunoGen (IMGN) is a Great Choice

December 4, 2023 | msn.com

ImmunoGen, AbbVie's $10B Deal Comes At 'Right Time' Analyst Says In Downgrade Note

December 4, 2023 | americanbankingnews.com

Insider Selling: ImmunoGen, Inc. (NASDAQ:IMGN) SVP Sells $113,154.72 in Stock